Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse.
Treatment efficiency of adjuvant therapy in breast cancer is revealed after several years by statistical evaluation, but this gives no answer for the individual patient. Having shown that circulating epithelial tumour cells (CETC) respond to neoadjuvant therapy in exactly the same way as the tumour, we monitored adjuvant therapy in 25 non-metastatic breast cancer patients. Nineteen patients with a decline or no change in number of CETC showed no relapse whereas six patients with a more than ten-fold increase had five distant and one local relapse, indicating that the dynamic of CETC in the individual patient is predictive of outcome.
Lobodasch
Kurt
K
Women's Hospital, Deutsches Rot-Kreuz Krankenhaus, Chemnitz-Rabenstein, Germany.
Fröhlich
Frank
F
Rengsberger
Matthias
M
Schubert
Rene
R
Dengler
Robert
R
Pachmann
Ulrich
U
Pachmann
Katharina
K
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D044584:Carcinoma, Ductal / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D018275:Carcinoma, Lobular / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating; D011237:Predictive Value of Tests
D015415:Biomarkers